Prescription-drug prices continue to seize headlines this election season. Recent drug-pricing scandals—involving EpiPen and Daraprim, older medicines used to treat asthma and malaria, respectively, as well as high list prices for new medicines to counter hepatitis C and cholesterol—seem to offer ammunition to critics who charge that drug manufacturers prioritize profits over patients.

But how are drug prices in the U.S. actually determined? Are the forces of competition being fully harnessed to yield positive results for patients? And how is high-deductible insurance, accelerating fast under Obamacare, affecting access to critical medicines?

Please join Manhattan Institute for a health-care symposium, as distinguished experts discuss the forces driving drug pricing in America—and explore promising new approaches for making medicines more affordable for patients.